Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.77 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | BTK | Q06187 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | TYK2 | P29597 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | TEK | Q02763 | 2/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 7/20 | 0.53 |
| ▸ | RAF1 | P04049 | 5/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974025 | 0.90 | LCK (0.69) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL2949721 | 0.87 | LCK (1.00) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL14107966 | 0.87 | LCK (0.81) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL4639353 | 0.84 | MAPK14 (0.58) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL2951415 | 0.82 | LCK (1.00) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL18164375 | 0.82 | LCK (0.77) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL14070183 | 0.80 | LCK (0.68) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL13878721 | 0.79 | LCK (0.69) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL2976092 | 0.78 | LCK (0.86) | LCKMAPK14KDRJAK3BTK | |
| SCHEMBL13219903 | 0.78 | LCK (0.81) | LCKMAPK14KDRJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1893605-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006103449-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | TIE1, TEK, FLT1 | LCK 902/4885MAPK14 3097/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.